Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119310 | 0.86 | STIM1 (0.37) | KDM4EALDH1A1KCNH2LMNAHTT | |
| SCHEMBL25524529 | 0.81 | TSHR (0.40) | TSHRKDM4ENPSR1ALDH1A1LMNA | |
| SCHEMBL5795783 | 0.81 | RIPK1 (0.38) | TSHRKDM4ENPSR1ALDH1A1KCNH2 | |
| SCHEMBL4538982 | 0.80 | KCNH2 (0.43) | TSHRKDM4ENPSR1ALDH1A1KCNH2 | |
| SCHEMBL13634258 | 0.80 | CCNT1 (0.38) | KDM4ENPSR1ALDH1A1KCNH2 | |
| SCHEMBL17542337 | 0.79 | TSHR (0.38) | TSHRLMNAMAPTPPARDHTT | |
| SCHEMBL6311761 | 0.78 | TSHR (0.48) | TSHRNPSR1KCNH2HPGDMAPK1 | |
| SCHEMBL5250114 | 0.78 | SMN1; SMN2 (0.53) | TSHRKDM4ENPSR1ALDH1A1KCNH2 | |
| SCHEMBL20898087 | 0.77 | TAAR1 (0.47) | TSHRALDH1A1MAPTPPARDPOLB | |
| SCHEMBL13623959 | 0.77 | ALDH1A1 (0.33) | TSHRKDM4ENPSR1ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618974-A1 | OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024107615-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107615-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-110015962-B | Stilbene analogs and methods of treating cancer | 肯塔基大学研究基金会 | 2022-03-15 | — | — | CN | disclosed |
| EP-2673250-B1 | STILBENE ANALOGS AND METHODS OF TREATING CANCER | UNIV KENTUCKY RES FOUND (US) | 2016-11-23 | — | — | EP | disclosed |
| CN-105622431-A | Stilbene analogs and methods of treating cancer | UNIV KENTUCKY | 2016-06-01 | — | — | CN | disclosed |
| US-9132102-B2 | Stilbene analogs and methods of treating cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-8846978-B2 | Electronic devices comprising novel phosphonic acid surface modifiers | IMPERIAL INNOVATIONS LTD. (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20140249161-A1 | STILBENE ANALOGS AND METHODS OF TREATING CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-8664276-B2 | Stilbene analogs and methods of treating cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120196874-A1 | STILBENE ANALOGS AND METHODS OF TREATING CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2012-08-02 | — | — | US | disclosed |
| WO-2012103457-A2 | STILBENE ANALOGS AND METHODS OF TREATING CANCER | UNIVERSITY OF KENTUCKY (US) | 2012-08-02 | — | — | WO | disclosed |
| CN-102459290-A | Electronic devices comprising novel phosphonic acid surface modifiers | GEORGIA TECH RES INST | 2012-05-16 | — | — | CN | disclosed |
| US-20120114974-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | NATIONAL SCIENCE FOUNDATION | 2012-05-10 | — | — | US | disclosed |
| EP-2417142-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | Georgia Tech Research Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| CN-102099941-A | Stable electrodes with modified work functions and methods for organic electronic devices | GEORGIA TECH RES INST | 2011-06-15 | — | — | CN | disclosed |
| US-20110114935-A1 | Stable electrodes with modified work functions and methods for organic electronic devices | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2304820-A1 | STABLE ELECTRODES WITH MODIFIED WORK FUNCTIONS AND METHODS FOR ORGANIC ELECTRONIC DEVICES | Georgia Tech Research Corporation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010115854-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010007081-A1 | STABLE ELECTRODES WITH MODIFIED WORK FUNCTIONS AND METHODS FOR ORGANIC ELECTRONIC DEVICES | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196874-A1 | STILBENE ANALOGS AND METHODS OF TREATING CANCER | BRCA1, APC, MSH2 | TSHR 953/4885KDM4E 2523/4885NPSR1 2946/4885 |
| US-20110114935-A1 | Stable electrodes with modified work functions and methods for organic electronic devices | EPCAM, EMD, L1CAM | TSHR 4240/4885KDM4E 484/4885NPSR1 3690/4885 |
| US-20140249161-A1 | STILBENE ANALOGS AND METHODS OF TREATING CANCER | BRCA1, APC, MSH2 | TSHR 953/4885KDM4E 2523/4885NPSR1 2946/4885 |
| US-20120114974-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | EFNA1, PHOSPHO1, EPHA6 | TSHR 4110/4885KDM4E 1389/4885NPSR1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.